Table 2.
Subset of data extraction table –five of 112 studies shown (full table in Additional file 3)
| Reference | Publication Year | Country | MDA Year(s) | Disease | Drugs delivereda | Method of delivery | Sampleb | Compliance rate | Reasons for non-compliance | Predictors of compliance (y/n)c | Notes on metrics/definitions |
|---|---|---|---|---|---|---|---|---|---|---|---|
| [31] | 2008 | Nigeria | 1996–2004 | RB | IVM | Community | 4800 surveyed | 49.96 % overall participation | n/a | No | Presented as ‘coverage’ yet discussed as ‘participation’ |
| [32] | 2007 | Sri Lanka | 2003 | LF | DEC + ALB | Community | 4358 surveyed | 71.4 % | Taking other medication (3.1 %), felt they did not need them (3.2 %), had forgotten to consume them (1.1 %), worried about adverse effects (0.8 %) | No | Compliance: those who consumed drug over eligible population |
| [34] | 2013 | India | 2008 | LF | DEC | Community | 571 eligible | 42.3 % | No motivation (24.7 %), drugs not supplied (22.5 %), absence at home (13.5 %), no faith (10.1 %), fear of side effects (10.1 %) and others: Forgotten, lack of prior IEC etc. (7.8 %), illness (7.3 %), wrong information (3.9 %) | No | Compliance: consumption of drug among those who received drug; defaulter: did not consume drug, or partially consumed drug, or those who were not supplied the drug by the drug distributors |
| [30] | 1991 | Liberia | 1987–1989 | RB | IVM | Community | 1987: 13,704; 1988: 13,977; 1989: 14,110 | 1987: 96.8 % (56.2 % of total pop); 1988: 96.6 % (57.7 % of total pop); 1989: 98.4 % (70.9 % of total pop) | n/a | No | Referred to as ‘those who accepted treatment’ using eligible population as denominator |
| [53] | 2006 | India | 2001–2003 | LF | DEC/DEC + ALB | Community | unspecified | MDA rounds 1–3 consumption rate: 34.9 %, 39.8 %, 41.7 % (of total population); 35.5 %, 40.3 %, 42.4 % (of eligible); 46.9 %, 51.7 %, 50 % (of drug recipients) | MDA rounds 1–3: not necessary (31.8 %, 52.9 %, 42.9 %), fear of side reactions (24.6 %, 20.7 %, 30.1 %), treatment for other diseases (8.9 %, 4.4 %, 11.3 %), no opinion/no response (19.2 %, 2.5 %, 6.5 %), partial consumption (6.6 %, 4.4 %, 5.6 %), others (8.9 %, 15.1 %, 3.6 %) | No | Referred to as consumption rate and presented in terms of total population, of eligible population, and of those who received drug |
asome studies may involve combinations of drugs (i.e. DEC + ALB) yet refer to only one drug (i.e. DEC) in the paper; the table includes only those drugs specifically named in the studies
bwhen available, the surveyed/interviewed population was taken as the sample; otherwise, eligible or total study population was taken
conly when statistically supported